DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

Abstract DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeutic strategies targeting DLL3 are varied, including antibody-drug conjugates (ADCs),...

Full description

Bibliographic Details

Main Authors:	Po-Lan Su, Karthik Chakravarthy, Naoki Furuya, Jeremy Brownstein, Jianhua Yu, Meixiao Long, David Carbone, Zihai Li, Kai He
Format:	Artigo
Language:	Inglês
Published:	BMC 2024-05-01
Series:	Molecular Cancer
Subjects:	DLL3 Small-cell lung cancer Antibody-drug conjugate T-cell engager Radioimmunotherapy
Online Access:	https://doi.org/10.1186/s12943-024-02012-z
Tags:	Add Tag No Tags, Be the first to tag this record!